Combining IL-2 or GM-CSF with immune checkpoint inhibitors, like anti-PD-1 antibodies, can enhance the immune system's ability to overcome tumor-induced immunosuppression and promote sustained immune responses 129. This evidence concerns the gene PDCD1 and neoplasm.